Align Technology shares have underperformed the Dow Jones Industrial Average over the past year, declining 1.6% compared with the Dow's 23.2% gain. The medical device company, known for its Invisalign clear aligners, has a market capitalization of $12.9 billion and saw its stock slip 13.8% from a 52-week high of $208.30. Over the past three months, ALGN rose 5.9%, trailing the Dow's 10.7% return, though it is up nearly 15% year-to-date, outpacing the Dow's 8.2% advance. The company reported first-quarter 2026 adjusted earnings of $2.58 per share on revenue of $1.04 billion, beating estimates, and announced a new $200 million share repurchase program while reaffirming full-year revenue growth of 3% to 4%. Analysts hold a consensus Moderate Buy rating with a mean price target of $208.23, implying a nearly 16% premium.
Align Technology IncArticle reports past underperformance vs Dow, but also notes earnings beat, buyback, and analyst rating; no clear directional catalyst.
Intuitive Surgical Inc